Steve Parker, Ph.D. and Michigan colleagues have received an AMP-T2D (Accelerating Medicines Partnership for Type 2 Diabetes) Consortium Award (UM1) from NIDDK

Steve Parker will lead a team working in the international AMP-T2D Consortium and is joined by University of Michigan colleagues: Arvind Rao, Laura Scott, Marci Brandenburg, and Mike Boehnke. Their proposal, which was joint with teams from the University of North Carolina, Harvard, and Stanford, titled “Bridging the gap between type 2 diabetes GWAS and therapeutic targets ” will help identify new treatment avenues for diabetes.